Niagen Bioscience, Inc.

DB:OCD1 Stock Report

Market Cap: €206.4m

Niagen Bioscience Management

Management criteria checks 2/4

Niagen Bioscience's CEO is Rob Fried, appointed in Jun 2018, has a tenure of 8.25 years. total yearly compensation is $8.38M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 2.1% of the company’s shares, worth €4.34M. The average tenure of the management team and the board of directors is 6.6 years and 9.4 years respectively.

Key information

Rob Fried

Chief executive officer

US$8.4m

Total compensation

CEO salary percentage7.71%
CEO tenure8.3yrs
CEO ownership2.1%
Management average tenure6.6yrs
Board average tenure9.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Fried's remuneration changed compared to Niagen Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

US$16m

Mar 31 2026n/an/a

US$19m

Dec 31 2025US$8mUS$646k

US$17m

Sep 30 2025n/an/a

US$20m

Jun 30 2025n/an/a

US$18m

Mar 31 2025n/an/a

US$14m

Dec 31 2024US$1mUS$500k

US$9m

Sep 30 2024n/an/a

US$1m

Jun 30 2024n/an/a

-US$1m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$1mUS$500k

-US$5m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023n/an/a

-US$11m

Dec 31 2022US$1mUS$500k

-US$17m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$27m

Dec 31 2021US$1mUS$500k

-US$27m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$1mUS$519k

-US$20m

Sep 30 2020n/an/a

-US$23m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$2mUS$487k

-US$32m

Compensation vs Market: Rob's total compensation ($USD8.38M) is above average for companies of similar size in the German market ($USD824.34K).

Compensation vs Earnings: Rob's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Rob Fried (66 yo)

8.3yrs
Tenure
US$8,381,900
Compensation

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of Niagen Bioscience, Inc. (formerly known as ChromaDex Corporation) since June 22, 2018 and its a Director since July 2015. Mr....

Leadership Team

NamePositionTenureCompensationOwnership
Frank Jaksch
Co-Founder & Chairman26.6yrsUS$268.08k2.92%
€ 6.0m
Robert Fried
CEO & Director8.3yrsUS$8.38m2.1%
€ 4.3m
Ozan Pamir
CFO & Principal Accounting Officer1.9yrsUS$648.24k0.017%
€ 36.0k
Carlos Lopez
Senior VP & General Counsel2.2yrsUS$558.01k0.0058%
€ 11.9k
Andrew Shao
Senior Vice President of Global Regulatory & Scientific Affairs6.6yrsno datano data
Michiko Kelley
Chief Marketing Officer1.8yrsno datano data
Chu Yan
Managing Director of Asia Pacific7.9yrsno datano data
Kendall Knysch
Head of Media Relations & Partnershipsno datano datano data
James Lee
Controllerno dataUS$374.47k0%
€ 0
Wesley Yu
Vice President of Financeno datano datano data
Lauren Rittman-Borzansky
Assistant Controllerno datano datano data
6.6yrs
Average Tenure
50yo
Average Age

Experienced Management: OCD1's management team is seasoned and experienced (6.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Frank Jaksch
Co-Founder & Chairman26.6yrsUS$268.08k2.92%
€ 6.0m
Robert Fried
CEO & Director11.2yrsUS$8.38m2.1%
€ 4.3m
Rudolph Emile Tanzi
Member of Scientific Advisory Board9.3yrsno datano data
Steven Rubin
Lead Independent Director9.5yrsUS$293.08k0.0088%
€ 18.2k
Roger Kornberg
Chairman of the Scientific Advisory Board12.2yrsno datano data
J. German
Member of Scientific Advisory Board12yrsno datano data
Ann Cohen
Independent Director4.4yrsUS$265.58k0%
€ 0
Wing Yu
Non-Executive Director9.1yrsUS$243.08k0%
€ 0
Kristin Patrick
Independent Director4.4yrsUS$258.08k0%
€ 0
Charles Brenner
Chief Scientific Advisor & Member of Scientific Advisory Board12yrsno datano data
Brunie Felding
Member of the Scientific Advisory Board7.2yrsno datano data
Wang Yu Ng
Non-Executive Director4.8yrsUS$245.58k0%
€ 0
9.4yrs
Average Tenure
65yo
Average Age

Experienced Board: OCD1's board of directors are considered experienced (9.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/18 09:05
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Niagen Bioscience, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey Van SinderenB. Riley Securities, Inc.
Susan AndersonCanaccord Genuity
Jeffrey MarkFarmhouse Equity Research